Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Perspective Therapeutics Inc. (CATX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: CATX (3-star) is a STRONG-BUY. BUY since 33 days. Profits (24.73%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.11
1 Year Target Price $14.11
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 340.76% | Avg. Invested days 46 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 258.31M USD | Price to earnings Ratio - | 1Y Target Price 14.11 |
Price to earnings Ratio - | 1Y Target Price 14.11 | ||
Volume (30-day avg) 14 | Beta 1.12 | 52 Weeks Range 1.60 - 16.55 | Updated Date 07/8/2025 |
52 Weeks Range 1.60 - 16.55 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6383.63% |
Management Effectiveness
Return on Assets (TTM) -15.56% | Return on Equity (TTM) -32.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 50430602 | Price to Sales(TTM) 175.6 |
Enterprise Value 50430602 | Price to Sales(TTM) 175.6 | ||
Enterprise Value to Revenue 68.73 | Enterprise Value to EBITDA -21.91 | Shares Outstanding 74228304 | Shares Floating 58942493 |
Shares Outstanding 74228304 | Shares Floating 58942493 | ||
Percent Insiders 18.83 | Percent Institutions 61.15 |
Upturn AI SWOT
Perspective Therapeutics Inc.
Company Overview
History and Background
Perspective Therapeutics, Inc. (formerly known as Isotope Technologies Group Inc.) is a radiopharmaceutical company focused on developing targeted alpha-particle radiotherapies and complementary imaging diagnostics for cancers. Founded in 1997 as Isotope Technologies Group Inc., the company initially focused on nuclear medicine technology and transitioned to radiopharmaceuticals. Significant milestones include advancements in its lead product candidate, 212Pb-DOTAMTATE, for neuroendocrine tumors, and expanding its pipeline through acquisitions and collaborations.
Core Business Areas
- Radiopharmaceuticals: Development and commercialization of targeted alpha-particle radiotherapies for various cancers. The main therapeutic target is neuroendocrine tumors with their lead product candidate, 212Pb-DOTAMTATE. Expanding to other cancer types is key to their strategy.
- Imaging Diagnostics: Development of complementary imaging diagnostics to identify patients who are most likely to benefit from their radiotherapies, ensuring personalized treatment approaches.
Leadership and Structure
The leadership team consists of seasoned professionals in radiopharmaceuticals and oncology. The organizational structure is typically hierarchical, with functional departments such as R&D, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- 212Pb-DOTAMTATE: Lead product candidate under development for the treatment of neuroendocrine tumors (NETs). It is a targeted alpha-particle radiotherapy designed to deliver radiation directly to cancer cells while minimizing damage to healthy tissue. Currently in clinical trials. Market share data is not yet available as it is not yet approved. Competitors include Novartis' Lutathera and Advanced Accelerator Applications (Novartis) somatostatin analogs.
- Imaging Agents: Diagnostic imaging agents used to identify patients suitable for treatment with 212Pb-DOTAMTATE and other radiotherapies. Market share data is not available. These imaging agents compete with other PET and SPECT tracers. Competitors include GE Healthcare and Siemens Healthineers.
Market Dynamics
Industry Overview
The radiopharmaceutical industry is experiencing growth driven by advancements in targeted therapies, increased demand for personalized medicine, and regulatory support for novel cancer treatments. The market is characterized by significant R&D investment and strategic collaborations.
Positioning
Perspective Therapeutics is positioned as an emerging player in the radiopharmaceutical market, focusing on targeted alpha-particle therapies. Its competitive advantage lies in its expertise in lead-212 based therapies and its potential to develop more effective and less toxic cancer treatments.
Total Addressable Market (TAM)
The global radiopharmaceutical market is projected to reach USD 15.1 billion by 2028. Perspective Therapeutics aims to capture a significant share of this market through its targeted therapies. Perspective's TAM consists of all those patients who might benefit from treatment with radiopharmaceuticals.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in targeted alpha-particle therapies
- Promising lead product candidate (212Pb-DOTAMTATE)
- Potential for personalized medicine approach through imaging diagnostics
- Intellectual property protection on key technologies
Weaknesses
- Limited commercialization experience
- Dependence on successful clinical trial outcomes
- High R&D expenses
- Smaller market capitalization than competitors
Opportunities
- Expansion into additional cancer indications
- Strategic partnerships with pharmaceutical companies
- Increasing demand for targeted cancer therapies
- Favorable regulatory environment for radiopharmaceuticals
Threats
- Competition from established radiopharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- NVS
- SNY
- ITMN
- ADRO
Competitive Landscape
Perspective Therapeutics is at a disadvantage compared to larger, established radiopharmaceutical companies. Its competitive advantage lies in its focus on targeted alpha-particle therapies and its potential to develop more effective and less toxic cancer treatments.
Major Acquisitions
iTheranostics, Inc.
- Year: 2022
- Acquisition Price (USD millions): 35
- Strategic Rationale: Acquisition expanded Perspective's theranostic capabilities by incorporating iTheranostics' technology for imaging solid tumors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the transition from nuclear medicine technology to radiopharmaceuticals and expanding its pipeline.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its lead product candidates. Analyst estimates vary widely based on these factors.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials for 212Pb-DOTAMTATE, expanding research collaborations, and exploring new cancer indications.
Summary
Perspective Therapeutics is an early-stage company with a focus on targeted alpha-particle radiotherapies, showing promise in its lead candidate 212Pb-DOTAMTATE. Its success hinges on positive clinical trial outcomes and securing regulatory approvals. The company faces competition from larger, established players and must manage its high R&D expenses effectively. Opportunities for growth lie in expanding its pipeline and entering strategic partnerships. Perspective must also focus on manufacturing capabilities to assure supply.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perspective Therapeutics Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2005-11-10 | CEO & Director Mr. Johan M. Spoor | ||
Sector Healthcare | Industry Medical Devices | Full time employees 138 | |
Full time employees 138 | |||
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.